https://doi.org/10.55788/3b4de9ff
Gut microbiota have a role in MS pathogenesis and may also influence MRI findings. Dr Federico Montini (Brigham and Women's Hospital, MA, USA) and colleagues set out to investigate whether gut microbiota are associated with 7T MRI metrics (notably cerebral LME and cortical lesions [CL]) in MS [1]. Enrolled were 28 participants with MS with a median age of 53 years; participants underwent 7T MRI scans and their stools were collected within 6 months after the scan. The researchers extracted stool DNA and performed 16S RNA-sequencing. LME and CLs were quantified by 2 blinded experts. The data science platform QIIME 2 (pronounced chime 2) and the statistical package Microbiome Multivariable Association with Linear Models (MaAsLin2) were deployed to detect associations.
The results showed that gut microbiota were associated with LME foci count, CL count and volume, and T2-lesion volume. âIt was very interesting to see that several butyrate-producing bacteria, such as Roseburia, Agathobacter, and Blautia, had a beneficial effect on LME [i.e. less LME foci], whereas Alistipes onderdonkii and Ruminococcus had a detrimental effect,â said Dr Montini. The volumetric data analysis revealed that gut microbiota are associated with volumes of the thalamus, caudate, globus pallidus, putamen, and deep grey matter; Butyrococcus and Prevotella had a beneficial effect (i.e. less atrophy), while, for example, Collinsella intestinales had a detrimental effect.
Stool MUC2 levels were also reduced. MUC2 is a major structural component of the protective mucus layer in the colon and small intestine. Stool MUC2 levels were negatively associated with LME foci count and with mucus-degrading bacteria abundance.
Dr Montini concluded that these findings may indicate that a disruption of the mucus layer facilitates a (too) narrow bacterial-immune system interaction, favouring LME development.
- Montini F, et al. Gut microbiota are associated with cortical lesions and leptomeningeal enhancement on 7T MRI. Abstract O008, ECTRIMS 2024, 18â20 September, Copenhagen, Denmark.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Risk factors and importance of persistent PIRA Next Article
Blood markers predict MS progression »
« Risk factors and importance of persistent PIRA Next Article
Blood markers predict MS progression »
Table of Contents: ECTRIMS 2024
Featured articles
Revised McDonald criteria allow earlier and more precise MS diagnosis
Approaches to RIS and MS converge
Diagnosis, Biomarkers, and Phenotypes
Revised McDonald criteria allow earlier and more precise MS diagnosis
Approaches to RIS and MS converge
AI versus clinicians: who diagnoses MS faster and better?
Blood markers predict MS progression
Gut microbiota modulate inflammation and cortical damage
Risk factors and importance of persistent PIRA
Vitamin D supplementation in progressive MS should be medically supervised
Treatment: Strategies
Encouraging real-world results of AHSCT to treat aggressive MS
CAR T-cell therapy in MS: in its infancy but highly anticipated
B cell-tailored dosing of ocrelizumab shows good results
First-line moderate-efficacy DMTs show similar efficacy
Treatment: Trials
Tolebrutinib slows disability worsening in relapsing MS
Frexalimab shows favourable safety and efficacy in OLE
Good safety of ozanimod over up to 8 years of treatment
Tolebrutinib slows disability in non-relapsing SPMS
High-dose simvastatin does not slow disability progression in SPMS
Pregnancy and Comorbidity Risks
Transfer of ocrelizumab into breastmilk is negligible
High genetic burden for depression associated with MS disease activity
More comorbidity is associated with worse clinical outcomes in MS
NMOSD/MOGAD
Ineffective response to EBV in MS not seen in similar diseases
Comparative effectiveness and safety of DMTs in NMOSD
Age, time, and treatment determine relapse risk in MOGAD
Related Articles
December 3, 2020
Intestinal IgA-producing B cells help curb CNS inflammation in MS
December 16, 2020
Decreased EDSS after plasma exchange in NMOSD
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com